Chronic lymphocytic leukaemia: Time for a risk-adapted approach;Chronische lymfatische leukemie: Hoog tijd voor een op het risico afgestemd beleid

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 3, 2003, Pages 104-110

  Kater, A P ^a   Van Oers, M H J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CHLORAMBUCIL; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PURINE DERIVATIVE; ADENOSINE DIPHOSPHATE RIBOSYL CYCLASE; CD38 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; B CELL LEUKEMIA; CANCER MORTALITY; CANCER STAGING; CELL DISRUPTION; CELL MATURATION; CHRONIC LYMPHATIC LEUKEMIA; DISEASE CLASSIFICATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; MORBIDITY; MULTIMODALITY CANCER THERAPY; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SOMATIC MUTATION; STEM CELL TRANSPLANTATION; CLASSIFICATION; GENETICS; METABOLISM; MUTATION; REVIEW;

ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MEMBRANE GLYCOPROTEINS; MUTATION; PROGNOSIS;

EID: 0037452345     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Caligaris-Cappio F, Hamblin TJ. B cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399-408.
2. Diehl LF, Karnell LH, Menck HR. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 1999;86:2684-92.
3. Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998;102:1515-25.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
5. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-7.
6. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
7. Rai KR. A critical analysis of staging CLL. In: Gale RP, Rai KR, editors. Chronic lymphocytic leukemia: recent progress and future directions. New York: Alan R.Liss; 1987. p. 252-64.
8. Binet JL, Lepoprier M, Dighiero G, Charron D, D'Athis P, Vaugier G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977;40:855-64.
9. Molica S. Prognostic factors in chronic lymphocytic leukemia. In: Cheson BD, editor. Chronic lymphoid leukemias. 2nd ed. New York: Marcel Dekker; 2001. p. 231-60.
10. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia, analysis of its prognostic significance. Br J Haematol 1986;62:507-75.
11. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987;60:2712-6.
12. Hamblin TJ, Orchard JA, Ibbotson RE, Davis Z, Thomas PW, Stevenson FK, et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002;99:1023-9.
13. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
14. Kröber A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002;100:1410-6.
15. Ibrahim S, Keating M, Do KA, O'Brien S, Huh YO, Jilani I, et al. CD38 expression as an important prognostic factor in B cell chronic lymphocytic leukemia. Blood 2001;98:181-6.
16. Mauro FR, De Rossi G, Burgio VL, Caruso R, Giannarelli D, Monarca B, et al. Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution. Haematologica 1994;79:334-41.
17. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delespesse G, et al. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996;88:4259-64.
18. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia. Blood 1999;93:1732-7.
19. Hallek M, Wanders L, Ostwald M, Busch R, Senekowitsch R, Stern S, et al. Serum beta(2)-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439-47.
20. Stilgenbauer S, Lichter P, Döhner H. Genomic aberrations in B cell chronic lymphocytic leukemia. In: Cheson BD, editor. Chronic lymphoid leukemias. 2nd ed. New York: Marcel Dekker; 2001. p. 353-76.
21. Oscier DG, Thompsett A, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997;89:4153-60.
22. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
23. French Cooperative Group on Chronic Lymphocytic Leukemia. Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients. Blood 1990;75:1414-21.
24. Dighiero G, Maloum K, Desablens B, Cazin B, Navarro M, Leblay R, et al. Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med 1998;338:1506-14.
25. French Cooperative Group on Chronic Lymphocytic Leukemia. Is the CHOP regimen a good treatment for advanced CLL? Results from two randomized clinical trials. Leuk Lymphoma 1994;13:449-56.
26. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd L, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750-7.
27. Robak T. Cladribine in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 2001;40:551-64.
28. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
29. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
30. O'Brien SM, Kantaijian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70.
31. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. Rituximab therapy of patients with B cell chronic lymphocytic leukemia. Blood 2001;98:1326-31.
32. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, et al. Rituximab using a thrice weekly dosing schedule in B cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64.
33. Dyer MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, et al. In vivo 'purging'of residual disease in CLL with Campath-1H. Br J Haematol 1997;97:669-72.
34. Keating MJ, Flinn I, Jain V, Binet JL, Hilhnen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61.
35. Lundin J, Kimby E, Bjorkholm M, Broliden PA, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100:768-73.
36. Esteve J, Montserrat E. Hematopoietic stem-cell transplantation for B cell chronic lymphocytic leukemia: current status. Rev Clin Exp Hematol 2000;4:167-78.
37. Van Besien K, Keralavarma B, Devine S, Stock W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia 2001;15:1317-25.
38. Esteve J, Villamor N, Colomer D, Cervantes F, Campo E, Carreras E, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia 2001;15:445-51.